CEO Quinn departs; interim CEO Kastenmayer named; restructuring cuts headcount 25%, prioritizes AGLE-177

Spyre Therapeutics, Inc.

CEO Anthony Quinn departed Aug 24, 2022 via mutual agreement; no disagreement; to serve as R&D Advisor then consultant through Sept 2023.
James Kastenmayer (General Counsel) appointed Interim CEO; base salary raised to $588,000, target bonus set at 50%.
Michael Hanley promoted to Chief Business Officer from Chief Commercial Officer.
Restructuring reduces headcount ~25% YTD; transitions patients out of pegzilarginase extension studies in Arginase 1 Deficiency.
Company prioritizes AGLE-177 development; expects cash runway extended into Q4 2023.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Anthony Quinn

President and Chief Executive Officer

SYRE · Spyre Therapeutics, Inc.

Effective: 2022-08-24
Successor: James Kastenmayer
Filed: August 25, 2022, 7:59 PM ET

Dr. Quinn ceased his role as the Company’s President and Chief Executive Officer, effective August 24, 2022 (the “CEO Transition Date”).

Appointed (interim)

James Kastenmayer

Interim Chief Executive Officer

SYRE · Spyre Therapeutics, Inc.

Effective: 2022-08-24
Filed: August 25, 2022, 7:59 PM ET

Effective as of the Transition Date, the Board appointed James Kastenmayer, the Company’s General Counsel and Corporate Secretary, to succeed Dr. Quinn as Interim Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony Quinn changed role as President and Chief Executive Officer at Spyre Therapeutics, Inc..

Action: ceased his role as
Role: President and Chief Executive Officer

Exact text from the filing

Dr. Quinn ceased his role as the Company’s President and Chief Executive Officer, effective August 24, 2022 (the “CEO Transition Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Kastenmayer was appointed as Interim Chief Executive Officer at Spyre Therapeutics, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

Effective as of the Transition Date, the Board appointed James Kastenmayer, the Company’s General Counsel and Corporate Secretary, to succeed Dr. Quinn as Interim Chief Executive Officer.

View on SEC.gov

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-229043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.